Exicure, Inc. (XCUR)
NASDAQ: XCUR · Real-Time Price · USD
1.010
-0.010 (-0.98%)
At close: Nov 3, 2026, 4:00 PM EST
1.000
-0.010 (-0.99%)
Pre-market: Nov 4, 2026, 4:34 AM EST
Exicure Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
1
Market Cap
6.61M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 500.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 28.83M | 29.31M | - |
| Dec 31, 2021 | -483.00K | -17.10M | - |
| Dec 31, 2020 | 16.61M | 15.32M | 1,181.87% |
| Dec 31, 2019 | 1.30M | 1.18M | 998.31% |
| Dec 31, 2018 | 118.00K | -9.60M | -98.79% |
| Dec 31, 2017 | 9.72M | 8.68M | 838.13% |
| Dec 31, 2016 | 1.04M | -1.35M | -56.62% |
| Dec 31, 2015 | 2.39M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
XCUR News
- 6 weeks ago - Exicure receives Nasdaq extension to regain stockholders’ equity compliance - TheFly
- 6 weeks ago - Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders' Equity Requirement - GlobeNewsWire
- 3 months ago - Exicure to settle GPCR Therapeutics milestone payment through equity issuance - TheFly
- 3 months ago - Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance - GlobeNewsWire
- 4 months ago - Exicure Announces Board and Committee Changes - GlobeNewsWire
- 4 months ago - Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement - GlobeNewsWire
- 5 months ago - Exicure receives noncompliance notification from Nasdaq - TheFly
- 5 months ago - Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q - GlobeNewsWire